Tissue factor pathway inhibitor is expressed by human monocyte-derived macrophages: Relationship to tissue factor induction by cholesterol and oxidized LDL

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 2, 1999, Pages 309-315

  Petit, Laure ^a   Lesnik, Philippe ^a   Dachet, Christiane ^a   Moreau, Martine ^a   Chapman, M John ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Anticoagulant activity; Atherothrombosis; Foam cells; Heparin; Procoagulant activity

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; ATHEROGENESIS; CELL CULTURE; CELL ISOLATION; FOAM CELL; HUMAN; HUMAN CELL; MACROPHAGE; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0033044353     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.2.309     Document Type: Article

References (58)

1. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med. 1986;314:488-500.
2. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasathy S, Carew TE, Butler S, Witztum JL, Steinberg D, Karkola K, Möttönen M, Nikkari T. Evidence for the presence of oxidatively modified low-density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84: 1089-1095.
3. Schroeder AP, Falk E. Vulnerable and dangerous coronary plaques. Atherosclerosis. 1995;118:S141-S149.
4. Fernandez-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A, Weng D, Shah PK, Badimon L. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol. 1994;23:1562-1569.
5. Marmur JD, Thiruvikraman SV, Fyfe BS, Guha A, Sharma SA, Ambrose JA, Fallon JT, Nemerson Y, Taubman MB. Identification of active tissue factor in human coronary atheroma. Circulation. 1996;94:1226-1232.
6. Wilcox JN. Thrombotic mechanisms in atherosclerosis. Coron Artery Dis. 1994;5:223-229.
7. Wada H, Kaneko T, Wakita Y, Minamikawa K, Nagaya S, Tamaki S, Deguchi K, Shirakawa S. Effect of lipoproteins on tissue factor activity and PAI-II antigen in human monocytes and macrophages. Int J Cardiol. 1994;47:S21-S25.
8. Lesnik P, Rouis M, Skarlatos S, Kruth HS, Chapman MJ. Uptake of exogenous free cholesterol induces upregulation of tissue factor expression in human monocyte-derived macrophages. Proc Natl Acad Sci USA. 1992;89:10370-10374.
9. Rapaport SI, Rao LVM. The tissue factor pathway: how it has become a 'prima ballerina.' Thromb Haemost. 1995;74:7-17.
10. Broze GJ. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol. 1992;29:159-169.
11. Novotny WF. Tissue factor pathway inhibitor. Semin Thromb Hemost. 1994;20:101-108.
12. Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem. 1988;263:6001-6004.
13. Wun T-C, Huang MD, Kretzmer KK. Immunoaffinity purification and characterization of lipoprotein-associated coagulation inhibitor from Hep G2 hepatoma, Chang liver and SK hepatoma cells. J Biol Chem. 1990; 265:16096-16101.
14. Van der Logt CPE, Dirven RJ, Reitsma PH, Bertina RM. Expression of tissue factor and tissue factor pathway inhibitor in monocytes in response to bacterial lipopolysaccharide and phorbolester. Blood Coagul Fibrinotysis. 1994;5:211-220.
15. McGee MP, Foster S, Wang XY. Simultaneous expression of tissue factor and tissue factor pathway inhibitor by human monocytes: a potential mechanism for localized control of blood coagulation. J Exp Med. 1994; 179:1847-1854.
16. Werling RW, Zacharski LR, Kisiel W, Bajaj SP, Memoli VA, Rousseau SM. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb Haemost. 1993;69:366-369.
17. Lesnik P, Dentan D, Vonica A, Moreau M, Chapman MJ. Tissue factor pathway inhibitor associated with LDL is inactivated by cell- and copper-mediated oxidation. Arterioscler Thromb Vasc Biol. 1995;15:1121-1130.
18. Dentan C, Lesnik P, Chapman MJ, Ninio E. Phagocytic activation induces formation of platelet-activating factor in human monocyte-derived macrophages and in macrophage-derived foam cells. Eur J Biochem. 1996;236:48-55.
19. Mougenot N, Lesnik P, Ramirez-Gil JF, Nataf P, Diczfalusy U, Chapman MJ, Lechat P. Effect of the oxidation state of LDL on the modulation of arterial vasomotor response in vitro. Atherosclerosis. 1997;133:183-192.
20. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
21. Rouis M, Nigon F, Lafuma C, Hornebeck W, Chapman MJ. Expression of elastase activity by human monocyte-macrophages is modulated by cellular cholesterol content, inflammatory mediators, and phorbol myristate acetate. Arteriosclerosis. 1990;10:246-255.
22. Fei HH, Berliner JA, Parhami F, Drake TA. Regulation of endothelial cell tissue factor expression by minimally oxidized LDL and lipopolysaccharide. Arterioscler Thromb. 1993;13:1711-1717.
23. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
24. Van der Logt CPE, Reitsma PH, Bertina RM. Intron-exon organization of the human gene coding for the lipoprotein-associated coagulation inhibitor: the Xa dependent inhibitor of the extrinsic pathway of coagulation. Biochemistry. 1991;30:1571-1577.
25. Siebert PD, Larrick W. PCR mimics: competitive DNA fragments for use as internal standards in quantitative PCR. Biotechniques. 1993;14: 244-249.
26. Stengel D, Antonucci M, Gaoua W, Dachet C, Lesnik P, Hourton D, Ninio E, Chapman MJ, Griglio S. Inhibition of lipoprotein lipase expression in human monocyte-derived macrophages is dependent upon LDL oxidation state: a key role for lysophosphatidylcholine. Arterioscler Thromb Vasc Biol. 1998;18:1172-1180.
27. Murphy LD, Herzog CE, Rudick JB, Fojo AT, Bates SE. Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. Biochemistry. 1990;29:10351-10356.
28. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
29. Lindahl AK, Jacobsen PB, Sandset PM, Abilgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coagul Fibrinolysis. 1991;2:713-721.
30. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI) Thromb Res. 1988;50: 803-813.
31. Archipoff G, Beretz A, Freyssinet JM, Klein-Soyer C, Brisson C, Cazenave JP. Heterogeneous regulation of constitutive thrombomodulin or inducible tissue-factor activities on the surface of human saphenous-vein endothelial cells in culture after stimulation by IL-1, TNF: thrombin or phorbol ester. Biochem J. 1991;273:679-684.
32. Gordon S, Clarke S, Greaves D, Doyle A. Molecular immunobiology of macrophages: recent progress. Curr Opin Immunol. 1995;7:24-33.
33. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA. 1990;87:8869-8873.
34. Carson SD, Perry GA, Pirruccello SJ. Fibroblast tissue factor: calcium and ionophore induce shape changes, release of membrane vesicles, and redistribution of tissue factor antigen in addition to increased procoagulant activity. Blood. 1994;84:526-534.
35. Satta N, Toti F, Feugeas O, Bohbot A, Dacharyprigent J, Eschwege V, Hedman H, Freyssinet JM. Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J Immunol. 1994;153:3245-3255.
36. Altieri DC, Morrissey JH, Edgington TS. Adhesive receptor Mac-1 coordinates the activation of factor X on stimulated cells of monocytic and myeloid differentiation: an alternative initiation of the coagulation protease cascade. Proc Natl Acad Sci USA. 1988;85:7462-7466.
37. Mattsson L, Johansson H, Ottosson M, Bondjers G, Wiklund O. Expression of lipoprotein lipase mRNA and secretion in macrophages isolated from human atherosclerotic aorta. J Clin Invest. 1993;92: 1759-1765.
38. Rosenfeld ME, Butler S, Ord VA, Lipton BA, Dyer CA, Curtiss LK, Palinski W, Witztum JL. Abundant expression of apoprotein E by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb. 1993;13:1382-1389.
39. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94: 2493-2503.
40. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA. 1989;86:2839-2843.
41. Rouis M, Nigon F, Eggerman TL, Brewer HB, Chapman MJ. Apolipoprotein E expression by human-monocyte-derived macrophages. Eur J Biochem. 1990;189:447-453.
42. Braze GJ, Lange GW, Duffin KL, McPhail L. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis. 1994;5: 551-559.
43. Galis ZS, Sukhova GK, Kranzhöfer R, Clark S, Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA. 1995;92:402-406.
44. Higuchi DA, Wun T-C, Likert KM, Braze GJJ. The effect of leucocyte elastase on tissue factor pathway inhibitor. Blood. 1992;79:1712-1719.
45. Girard TJ, Warren LA, Novotny WF, Bejcek BE, Miletich JP, Broze GJ. Identification of the 1.4 kb and 4.0 kb messages for the lipoprotein-associated coagulation inhibitor and expression of the encoded protein. Thromb Res. 1989;55:37-50.
46. Harenberg J, Malsch R, Heene DL. Tissue factor pathway inhibitor: proposed heparin recognition region. Blood Coagul Fibrinolysis. 1995;6: S50-S56.
47. Warshawski I, Broze GJ, Schwartz AL. The low density lipoprotein receptor-related mediates the cellular degradation of tissue factor pathway inhibitor. Proc Natl Acad Sci USA. 1994;91:6664-6668.
48. Lupu F, Lupu C, Scully M, Saroj D, Kakkar V. Localisation of tissue factor pathway inhibitor in normal and atherosclerotic vessels. Thromb Haemost. 1995;73:1184. Abstract.
49. Van den Eijnden MMED, Steenhaur S, Reitsma PH, Bertine RM. Tissue factor expression during monocyte-macrophages differentiation. Thromb Haemost. 1997;77:1129-1136.
50. Bach R, Gentry R, Nemerson Y. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidyl serine. Biochemistry. 1986;25:4007-4020.
51. Repte D, Gentry R, Nemerson Y. Tissue factor (TF) in phosphatidyl choline (PC) has a higher kcat than tissue factor in phosphatidyl serine (PS): implications for the role of acidic lipids in coagulation. Thromb Haemost. 1995;73:1094. Abstract.
52. Ruf W, Rehemtulla A, Edgington TS. Phospholipid-independent and -dependent interactions required for tissue factor receptor and cofactor function. J Biol Chem. 1991;266:2158-2166.
53. Zioncheck TF, Roy S, Vehar GA. The cytoplasmic domain of tissue factor is phosphorylated by a protein kinase C-dependent mechanism. J Biol Chem. 1991;267:3561-3564.
54. Rickles FR, Hair GA, Zeff RA, Lee E, Bona RD. Tissue factor expression in human leukocytes and tumor cells. Thromb Haemost. 1995;74: 391-395.
55. Fymys B, Claus R, Wolf G, Deigner HP. Oxidized LDL stimulates protein kinase C activity and expression of PKC-isotypes via prostaglandin-H-synthase in P388D1 cells. Adv Exp Med Biol. 1997;407:93-98.
56. Matsumura T, Sakai M, Kobori S, Biwa T, Takemura T, Matsuda H, Hakamata H, Horiuchi S, Shichiri M. Two intracellular signaling pathways for activation of protein kinase C are involved in oxidized LDL-induced macrophage growth. Arterioscler Thromb Vasc Biol. 1997; 17:3013-3020.
57. Koyama T, Nishida K, Ohdama S, Sawada M, Murakami N, Hirosawa S, Kuriyama R, Matsuzawa K, Hasegawa R, Aoki N. Determination of plasma tissue factor antigen and its clinical significance. Br J Haematol. 1994;87:343-347.
58. Drew AF, Davenport P, Apostolopoulos J, Tipping PG. Tissue factor pathway inhibitor expression in atherosclerosis. Lab Invest. 1997;77: 291-298.